FDA Clearance Tracker · P100034
NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
Last checked: Nov 20, 2026Latest source record: Apr 8, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Apr 8, 2011
Approved
Time to decision
235 days
Received Aug 16, 2010. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P100034
- Device name
- NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
- Applicant
- Novocure, GmbH
- Applicant location
- Baar
- Received
- Aug 16, 2010
- Decided
- Apr 8, 2011
- Decision
- Approved
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 45 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE NOVOTTF-100A SYSTEM. THE DEVICE IS INDICATED FOR TREATMENT OF ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY- CONFIRMED GLIOBLASTOMA MULTIFORME, FOLLOWING HISTOLOGICALLY- OR RADIOLOGICALLY- CONFIRMED RECURRENCE IN THE SUPRATENTORIAL REGION OF THE BRAIN AFTER RECEIVING CHEMOTHERAPY. THE DEVICE IS INTENDED TO BE USED AS A MONOTHERAPY, AND IS INTENDED AS AN ALTERNATIVE TO STANDARD MEDICAL THERAPY FOR GBM AFTER SURGICAL AND RADIATION OPTIONS HAVE BEEN EXHAUSTED.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code NZK (Stimulator, low electric field, tumor treatment).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Novocure, GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- Optune LuaPMA
P230042 · Decided Oct 15, 2024 · 305 days after receipt
Device type: Electrical tumor treatment fields for non-small cell lung cancer (SDA) · Anesthesiology & Respiratory
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)PMA supplement
P100034-S013 · Decided Oct 5, 2015 · 178 days after receipt · Panel Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.